Insulin analogs represent one of the earliest major breakthroughs in peptide hormone research. The discovery of insulin in the early 1920s was one of the earliest major breakthroughs in peptide hormone research. Modern insulin analogs are lab-modified human insulins that can alter the speed or duration of action in the body, making them better match the body's insulin needs. Traditional human insulin has the same amino acid sequence as natural human insulin but cannot fully mimic the timing of natural insulin secretion.
Modern insulin analogs, through precise structural adjustments, provide more flexible and physiologically appropriate options for diabetes management. This reflects the core advantage of peptide drugs in mimicking the body's own signaling molecules. While many traditional drugs work by blocking or altering biological pathways, peptide drugs often mimic the body's own signaling molecules. They have more complex structures and can precisely target specific biological pathways, making them potentially highly effective in appropriate situations.
Currently, about 85 peptide drugs have received FDA approval, and insulin analogs are an important part of them. Administration methods for peptide products include oral, nasal, injection, and topical. Because peptides are easily broken down by the digestive system, many therapeutic peptides are administered by injection. To improve the absorption rate of oral peptides, researchers are developing delivery technologies such as polymeric nanoparticles and microneedles. Medical professionals typically determine usage duration based on treatment goals and efficacy changes, and track effects by monitoring indicators such as blood sugar. Healthy habits like regular exercise may enhance the benefits of certain peptides. As technology advances, the application of insulin analogs in diabetes management continues to optimize, providing patients with more precise and convenient treatment options.